BioCentury
ARTICLE | Company News

Remedyne, Bayer deal

March 11, 2002 8:00 AM UTC

BAY granted Remedyne a license to its carcinoembryonic antigen (CEA) gene, for use in Remedyne's RemeStim-CEA cancer immunotherapeutic for U.S. oncology markets. BAY will have an option to acquire co...